Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | KRd improves response rates vs. VRd in newly diagnosed myeloma

Ola Landgren • 3 Dec 2018
ASH 2018
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone Lenalidomide
CoMMpass

Triplet regimens containing a proteasome inhibitor and immunomodulatory agent are the standard of care for newly diagnosed multiple myeloma (NDMM). Here, Ola Landgren, MD, PhD, of the Memorial Sloan Kettering Cancer Center, NY, discusses the results of the CoMMpass study (NCT01454297), which investigated carfilzomib-lenalidomide-dexamethasone (KRd) vs. bortezomib-lenalidomide-dexamethasone (VRd) in NDMM. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Ola Landgren

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
3:51
Should HR-SMM be treated before progression to NDMM?
Ola Landgren • 20 Dec 2023
3:31
ADVANCE: Dara-KRd versus KRd in patients with NDMM
Ola Landgren • 20 Dec 2023

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals